Fully individualized models for cross-sectional and longitudinal network-based tau spread
Heterogeneity in regional tau burden limits evaluation of disease progression using one-size-fits-all approaches. Prior work using tau positron emission tomography (PET) has highlighted the important role of connectivity to epicenters of tau pathology in explaining this heterogeneity. However, previous studies using population-based epicenters or connectomes fall short of a fully individualized approach to predicting regional tau burden. We use diffusion MRI-derived structural connectomes to assess the prediction of regional tau burden using distance along individual structural connectomes from individualized epicenters of tau pathology both cross-sectionally and longitudinally. Fully individualized models of connectivity and epicenters outperformed models using either population-based connectomes or epicenters in explanation of cross-sectional and longitudinal regional tau burden, improved prediction in validation datasets, and produced stronger single-subject level prediction. Together, these findings demonstrate the power of a fully individualized approach to explain regional tau heterogeneity and provide the strongest <i>in vivo</i> evidence to date for network-based spread of tau pathology.
Authors
- Ilya M. Nasrallah (ORCID: https://orcid.org/0000-0003-2346-7562)
- S. J. Wolk (ORCID: https://orcid.org/0000-0002-0826-9261)
- Corey T. McMillan (ORCID: https://orcid.org/0000-0002-7581-6405)
- Sandhitsu R. Das (ORCID: https://orcid.org/0000-0003-0530-2887)
- John A. Detre (ORCID: https://orcid.org/0000-0002-8115-6343)
- Paul A. Yushkevich (ORCID: https://orcid.org/0000-0001-8543-4016)
- Christopher Brown (ORCID: https://orcid.org/0000-0003-2057-3976)
Institutions
- University of Pennsylvania (US)
Publication Details
- Journal
- Imaging Neuroscience
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1162/imag.a.1053
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Foundation for the National Institutes of Health
- Alzheimer's Association
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Pennsylvania Department of Health
- Biogen
- Meso Scale Diagnostics
- Alzheimer's Disease Neuroimaging Initiative
- BioClinica
- Novartis Pharmaceuticals Corporation
- Northern California Institute for Research and Education
- Eisai
- Servier
- H. Lundbeck A/S
- IXICO
- National Institutes of Health
- Genentech
- Avid Radiopharmaceuticals
- Canadian Institutes of Health Research